SCHEMBL8842689

SCHEMBL8842689

CCOC(=O)CC(C)N1C(=O)c2cc(C#CCCC(=O)c3cccnc3NC(=O)OC(C)(C)C)ccc2N(C)C(=O)C1c1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.34
HDAC6 Q9UBN7 4/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC11 Q96DB2 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
MDM2 Q00987 2/20 0.33
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRA6 Q16445 1/20 0.32
RIPK1 Q13546 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7323957 0.90 RIPK1 (0.34) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL7327662 0.84 GBA1 (0.32) RIPK1GBA1
SCHEMBL7330784 0.83 RIPK1 (0.34) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL7331244 0.83 RIPK1 (0.34) MDM2RIPK1GBA1
SCHEMBL7321486 0.83 HDAC1 (0.38) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL7322551 0.83 GBA1 (0.31) RIPK1GBA1
SCHEMBL7326023 0.81 HDAC1 (0.31) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL7330387 0.80 SCN9A (0.33) RIPK1
SCHEMBL9264467 0.80 MDM2 (0.34) MDM2GABRA1GABRG2GABRB3GABRA5
SCHEMBL7331770 0.78 GBA1 (0.31) RIPK1GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5663166-A ANTICOAGULANTS OF 1,4-BENZODIAZEPINE-2,5-DIONE AND 2-BENZOAZEPINE-1,4-DIONE DERIVATIVES; PREVENTS FIBRINOGEN BINDING NECESSARY FOR PLATELET AGGREGATION; SIDE EFFECT REDUCTION, E.G. EXCESSIVE BLEEDING GENENTECH, INC. (US) 1997-09-02 US disclosed